Jan. 13, 2015 from 11 a.m. to noon
Hess Center 1st Floor
TMII Large Conference Room 117
- Nick Devoogdt, PhD
- Lab Invivo Cellular and Molecular Imaging,
- Free University of Brussels
Abstract:. Nanobodies are small (10-15kD) antigen-binding proteins derived from the variable heavy-chain domain (VHH) of unique single-chain antibodies that are naturally present in camelidae. Due to their beneficial biochemical and pharmacokinetic properties, Nanobodies are ideally suited as tracers for molecular imaging. For instance, they have high affinities (nM range) and specificities for their target antigen, are easy to generate and can be recombinantly produced in high amounts. Nanobodies also invade dense cellular structures and are quickly removed from the circulation via renal clearance; They are also highly soluble and stable, can be chemically modified and linked with a range of fluorescent dyes and radionuclides; Hence, nanobody-derived tracers can generate high contrast images fast after injection. We here present our experience with radio- and fluorescently-labeled Nanobodies as tracers for molecular imaging of a variety of pathologies. In particular, we will present the generation and biochemical evaluation of nanobodies targeting a diversity of membrane receptors present on diseased cells and show some examples of noninvasive imaging (SPECT, PET and optical) of these cells in mouse models of cancer, arthritis and atherosclerosis, and the potential clinical translation of these findings.